Redeye comments on BioInvent's Q1 report 2026, which was a transitional quarter with limited news since our Q4 review. The mid-year readouts from BI-1206 in the triplet study in NHL and from BI-1808 in T-cell lymphoma will drive the share and potentially position these assets for a deal.
LÄS MER
